With the efforts of researchers and pharmaceutical experts, Iran succeeded in producing the anti-Blood lipids new drug after the United Kingdom for the first time in the Middle East.
Cholesterol is one of the essential fats in the body and it plays a very important role in the structure of some organs such as the nervous system as well as some hormones and cell membranes.
But the abnormal increase is harmful and It can precipitate on the arteries wall, causing stiffness of the artery or atherosclerosis.
Eventually, myocardial infarction and strokes occur by creating a blood clot.
Therefore, coronary artery disease and myocardial infarction are among the major causes of death in the world and especially in Iran.
One of the major risk factors for myocardial infarction is hypertension or hyperlipidemia, which includes cholesterol and LDL, which should be controlled in childhood.
If your blood lipid is high, you should be treated with anti- lipids drugs such as statins to were prevented myocardial infarction and strokes.
With the discovery and making a group of drugs which we now call them statins, dramatic changes have been made in achieving the therapeutic goal of lowering blood lipid Cholesterol type.
The latest research achievements, was led to the release of the latest generation of statins called Rosuvastatin that fortunately has reached the production stage in Iran.
Abidi company is proud to be the first in Iran to produce Resvastatin (one of the most widely used anti-Blood lipids drug in the world) under the brand “Ropixon”, a new tool available to medical staff and patients to lower cholesterol and LDL (bad fat) and increase HDL (Good fat).